Edward T. Mathers - Sep 12, 2024 Form 4 Insider Report for MBX Biosciences, Inc. (MBX)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MBX	Stock Option (Right to Buy)	Award	$0	+16K		$0.00	16K	Sep 12, 2024	Common Stock	16K	$16.00	Direct	F1

Showing 1 to 1 of 1 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.